Abstract: Objective　To evaluate the efficacy of cyclosporine A (CSA) in children with non-severe aplastic anemia (NSAA). Methods　A retrospective analysis of clinical data of 126 children with NSAA treated with CSA in our hospital between January 2005 and June 2014 was performed. Results　Of the 126 cases, 76 were male, and 50 were female, with a median age of 7 years and 11 months old (1 year and 11 months-14 years old), respectively. The median follow-up time was 14.5 months (3-79 months). There were 78 (61.9%) cases of transfusion-independent NSAA, and 48 (38.1%) cases of transfusion-dependent NSAA. After receiving CSA treatment, 14.1% patients with transfusion-independent NSAA achieved complete remission, 80.8% cases kept transfusion-independent NSAA, and 5.2% children progressed to transfusion-dependent NSAA or severe aplastic anemia/very severe aplastic anemia (SAA/VSAA). The response rate of CSA was 42.3%. 16.7% cases with transfusion-dependent NSAA achieved complete remission, 60.4% patients improved to transfusion-independent NSAA, and 23% children maintained transfusion-dependent NSAA or progressed to SAA/VSAA. The response rate of CSA in patients with transfusion-dependent NSAA was 77.1%. The overall response rate of CSA in 126 NSAA patients was 55.6%. Conclusions　CSA treatment can markedly reduce the probability of progression in children with NSAA. The patients can obtain benefits from early treatment of CSA. However, the complete remission rate of CSA was low, further clinical trials are necessary to establish more effective regimens for NSAA.